

Deprenyl Inc.							
Balance Sheet as at 31 March 2017							
		USD	(₹ in thousand)	USD	(₹ in thousand)	USD	(₹ in thousand)
Notes		As at 31 March 2017		As at 31 March 2016		As at 01 April 2015	
ASSETS							
Non-current assets							
Other Intangible assets		-	-	1,350,000	89,438	1,350,000	84,375
Advance payment of income tax		6,997	454	20,250	1,342	20,250	1,266
Total		6,997	454	1,370,250	90,780	1,370,250	85,641
Current assets							
Financial assets							
i. Trade receivables	1(a)	7,750	503	-	-	-	-
ii. Cash and cash equivalents	1(b)	98,161	6,366	34,334	2,274	34,324	2,145
iii. Short Term Loans & Advances	1(c)	2,000,000	129,700	2,000,000	132,500	2,000,000	125,000
Other current assets	2	561,080	36,384	459,683	30,453	358,006	22,375
Total current assets		2,666,991	172,953	2,494,017	165,227	2,392,330	149,520
Total assets		2,673,988	173,407	3,864,267	256,007	3,762,580	235,161
EQUITY AND LIABILITIES							
Equity							
Equity share capital	3(a)	15	1	15	1	15	1
Other equity	3(b)	2,194,469	142,310	3,122,735	206,880	3,021,281	188,829
Equity attributable to equity holders of the Parent		2,194,484	142,311	3,122,750	206,881	3,021,296	188,830
LIABILITIES							
Non-current liabilities							
Deferred tax liabilities(Net)		-	-	459,000	30,409	459,000	28,688
Total non-current liabilities		-	-	459,000	30,409	459,000	28,688
Current liabilities							
Financial liabilities							
Trade payables	4	493,341	31,993	282,517	18,717	282,284	17,643
Current tax liabilities	5	(13,837)	(897)	-	-	-	-
Total current liabilities		479,504	31,096	282,517	18,717	282,284	17,643
Total liabilities		479,504	31,096	741,517	49,126	741,284	46,331
Total equity and liabilities		2,673,988	173,407	3,864,267	256,007	3,762,580	235,161
PRAKASH C BISHT							
CFO (LSI) & Sr. VP (Group Accounts)							
Place: Noida							
Date: 22 May, 2017							

Deprenyl Inc.

Statement of Profit and Loss for the year ended 31 March 2017

		USD	(₹ in thousand)	USD	(₹ in thousand)
	Notes	For the year ended 31 March 2017		For the year ended 31 March 2016	
Revenue from operations	6	71,577	4,794	-	-
Other income	7	101,398	6,803	101,679	6,648
Total income		172,975	11,597	101,679	6,648
Expenses					
Other expenses	8	1,550,225	104,381	225	15
Total expenses		1,550,225	104,381	225	15
(Loss) / Profit before tax		(1,377,250)	(92,783)	101,454	6,633
Tax expense					
Current tax		10,016	673	-	-
Deferred tax		(459,000)	(30,923)	-	-
Total tax expense		(448,984)	(30,250)	-	-
(Loss) / Profit for the Year		(928,266)	(62,534)	101,454	6,633
Other comprehensive income					
Items that will be reclassified to profit or loss					
Exchange differences on translation of foreign operations		-	(2,036)	-	11,418
Other comprehensive income for the year, net of tax		-	(2,036)	-	11,418
Total comprehensive income for the year		(928,266)	(64,570)	101,454	18,051
(Loss) / Profit is attributable to:					
Equity holders of the Parent		(928,266)	(62,534)	101,454	6,633
Non-controlling interests		-	-	-	-
Total comprehensive income is attributable to:		(928,266)	(62,534)	101,454	6,633
(Loss) / Profit is attributable to:					
Equity holders of the Parent		(928,266)	(64,570)	101,454	18,051
Non-controlling interests		-	-	-	-
Total comprehensive income is attributable to:		(928,266)	(64,570)	101,454	18,051

PRAKASH C BISHT
CFO (LSI) & Sr. VP (Group Accounts)

Place: Noida
Date: 22 May, 2017

Deprenyl Inc.

Statement of Cash Flows for the year ended 31 March 2017

	USD	(₹ in thousand)	USD	(₹ in thousand)
	For the year ended 31 March 2017		For the year ended 31 March 2016	
A. Cash flow from operating activities				
Net (loss) / profit before tax	(1,377,250)	(92,783)	101,454	6,633
Adjustments :				
Impairment of intangible assets	1,350,000	90,950	-	-
Interest income	(101,398)	(6,803)	(101,679)	(6,648)
Operating cash flow before working capital changes	1,248,602	84,147	(101,679)	(6,648)
	(128,648)	(8,636)	(225)	(15)
Increase in trade and other receivables	(7,750)	(520)	-	-
Increase in trade payables, provisions and other liabilities	210,825	14,138	233	15
Cash generated from operations	74,427	4,982	8	(0)
Income tax paid (net of refund)	(10,600)	(711)	-	-
Net cash generated from operating activities	63,827	4,271	8	(0)
B. Cash flow from investing activities				
Interest received	-	-	2	-
Net cash used in investing activities	-	-	2	-
C. Effect of exchange rate changes	-	(179)	-	129
Net decrease in cash and cash equivalents (A+B+C)	63,827	4,092	10	129
Add: cash and cash equivalents at the beginning of year	34,334	2,274	34,324	2,145
Cash and cash equivalents at the end of the year	98,161	6,366	34,334	2,274
 PRAKASH C BISHT CFO (LSI) & Sr. VP (Group Accounts) Place: Noida Date: 22 May, 2017				

Deprenyl Inc.

Notes to the financial statements for the year ended 31 March 2017

1 (a) Trade receivables

	USD	(₹ in thousand)	USD	(₹ in thousand)	USD	(₹ in thousand)
	As at		As at		As at	
	31 March 2017		31 March 2016		01 April 2015	
Trade receivables	7,750	503	-	-	-	-
Total receivables	7,750	503	-	-	-	-
Current portion	7,750	503	-	-	-	-
Non-current portion	-	-	-	-	-	-

Break-up of security details

	USD	(₹ in thousand)	USD	(₹ in thousand)	USD	(₹ in thousand)
	As at		As at		As at	
	31 March 2017		31 March 2016		01 April 2015	
Unsecured, considered good	7,750	503	-	-	-	-
Total trade receivables	7,750	503	-	-	-	-

1 (b) Cash and cash equivalents

	USD	(₹ in thousand)	USD	(₹ in thousand)	USD	(₹ in thousand)
	As at		As at		As at	
	31 March 2017		31 March 2016		01 April 2015	
Balances with banks						
- in current accounts	98,161	6,366	34,334	2,274	34,324	2,145
Total cash and cash equivalents	98,161	6,366	34,334	2,274	34,324	2,145

1 (c) . SHORT TERM LOANS AND ADVANCES

	USD	(₹ in thousand)	USD	(₹ in thousand)	USD	(₹ in thousand)
	As at		As at		As at	
	31 March 2017		31 March 2016		01 April 2015	
- Loans to related parties	2,000,000	129,700	2,000,000	132,500	2,000,000	125,000
Total short term loans and advances	2,000,000	129,700	2,000,000	132,500	2,000,000	125,000

2. OTHER FINANCIAL ASSETS

	USD	(₹ in thousand)	USD	(₹ in thousand)	USD	(₹ in thousand)
	As at		As at		As at	
	31 March 2017		31 March 2016		01 April 2015	
Advance recoverable in cash & kind from related parties	561,080	36,384	459,683	30,453	358,006	22,375
Total other financial assets	561,080	36,384	459,683	30,453	358,006	22,375

Deprenyl Inc.

Notes to the financial statements for the year ended 31 March 2017

4. Trade payables

	USD	(₹ in thousand)	USD	(₹ in thousand)	USD	(₹ in thousand)
	As at 31 March 2017		As at 31 March 2016		As at 01 April 2015	
Current						
Trade payables	493,341	31,993	282,517	18,717	282,284	17,643
Total trade payables	493,341	31,993	282,517	18,717	282,284	17,643

5. Current tax liabilities

	USD	(₹ in thousand)	USD	(₹ in thousand)
Particulars	As at 31 March 2017		As at 31 March 2016	
Opening balance	-	-	-	-
Add: Current tax payable for the year	10,016	673	-	-
Less: Taxes paid	(23,853)	(1,570)	-	-
Closing balance	(13,837)	(897)	-	-

Deprenyl Inc.

Notes to the financial statements for the year ended 31 March 2017

3 (a) Equity share capital

	(₹ in thousand)
Balance as at 1 April 2015	15
Additions during the year	-
Balance as at 31 March 2016	15
Additions during the year	-
Balance as at 31 March 2017	15

3 (b) Other Equity

	Reserves and Surplus				USD
	Securites premium	Retained earnings	Foreign currency translation reserve	Total	
As at 1 April 2015	1,400,085	1,621,196	-	3,021,281	
Loss for the year		101,454		101,454	
Other comprehensive income				-	
Total comprehensive income for the year		101,454		101,454	
As at 31 March 2016	1,400,085	1,722,650	-	3,122,735	

	Reserves and Surplus				
	Securites premium	Retained earnings	Foreign currency translation reserve	Total	
As at 1 April 2016	1,400,085	1,722,650	-	3,122,735	
Loss for the year		(928,266)		(928,266)	
Other comprehensive income				-	
Total comprehensive income for the year		(928,266)		(928,266)	
As at 31 March 2017	1,400,085	794,384	-	2,194,469	

Deprenyl Inc.

Notes to the financial statements for the year ended 31 March 2017

3 (a) Equity share capital

(₹ in thousand)

Balance as at 1 April 2015	1
Deductions during the year on account of capital reduction	
Balance as at 31 March 2016	1
Additions during the year	-
Balance as at 31 March 2017	1

3 (b) Other Equity

(₹ in thousand)

	Reserves and Surplus			
	Securites premium	Retained earnings	Foreign currency translation reserve	Total
As at 1 April 2015	69,892	118,937	(0)	188,829
Loss for the year		6,633		6,633
Other comprehensive income			11,418	11,418
Total comprehensive income for the year		6,633	11,418	18,051
As at 31 March 2016	69,892	125,570	11,418	206,880

	Reserves and Surplus			
	Securites premium	Retained earnings	Foreign currency translation reserve	Total
As at 1 April 2016	69,892	125,570	11,418	206,880
Loss for the year		(62,534)		(62,534)
Other comprehensive income			(2,036)	(2,036)
Total comprehensive income for the year		(62,534)	(2,036)	(64,570)
As at 31 March 2017	69,892	63,036	9,382	142,310

Deprenyl Inc.

Notes to the financial statements for the year ended 31 March 2017

3 (c). SHARE CAPITAL

	USD	(₹ in thousand)	USD	(₹ in thousand)	USD	(₹ in thousand)
	As at 31 March 2017		As at 31 March 2016		As at 01 April 2015	
Authorised						
3000 (31 March 2016: 3000; 1 April 2015: 3000) equity shares of USD 0.01 each	30	-	30	-	30	-
Issued, Subscribed & Paid up						
1500 (31 March 2016: 1500; 1 April 2015: 1500) equity shares of USD 0.01 each	15	1	15	1	15	1

(i) The Company has only one class of shares referred to as equity shares having par value of USDD 0.01. Each holder of equity shares is entitled to one vote per share.

(ii) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

(iii) The details of shareholders holding more than 5% shares is set out below:

Name of the shareholder	As at 31 March 2017		As at 31 March 2016		As at 01 April 2015	
	No of shares	% holding	No of shares	% holding	No of shares	% holding
Draximage Limited, Cyprus	-	-	1,500	100	1,500	100
Jubilant Pharma Ltd, Singapore	1,500	100	-	-	-	-

(iv) Shares held by holding company/ultimate holding company and/or their subsidiaries/associates

Out of the equity Shares issued by the company, shares held by it's holding company/ultimate holding company and/or their subsidiaries/associates are as below:

Name of the shareholder	As at 31 March 2017		As at 31 March 2016		As at 01 April 2015	
	No of shares	(₹ in thousand)	No of shares	(₹ in thousand)	No of shares	(₹ in thousand)
Draximage Limited, Cyprus	-	-	1,500	1	1,500	1
Jubilant Pharma Ltd, Singapore	1,500	1	-	-	-	-

(v) The reconciliation of the number of shares outstanding is set out below:

Particulars	As at 31 March 2017		As at 31 March 2016		As at 01 April 2015	
	No of shares	(₹ in thousand)	No of shares	(₹ in thousand)	No of shares	(₹ in thousand)
Numbers of shares at the beginning	1,500	1	1,500	1	1,500	1
Add: Shares issued during the year	-	-	-	-	-	-
Numbers of shares at the end	1,500	1	1,500	1	1,500	1

Deprenyl Inc.

Notes to the financial statements for the year ended 31 March 2017

6. Revenue from operations

Particulars	USD		USD	
	(₹ in thousand)		(₹ in thousand)	
	For the year ended		For the year ended	
	31 March 2017		31 March 2016	
Royalty Revenues	71,577	4,794	-	-
Total revenue from operations	71,577	4,794	-	-

7. Other income

Particulars	USD		USD	
	(₹ in thousand)		(₹ in thousand)	
	For the year ended		For the year ended	
	31 March 2017		31 March 2016	
Interest Income	101,398	6,803	101,679	6,648
Total other income	101,398	6,803	101,679	6,648

8. Other expenses

Particulars	USD		USD	
	(₹ in thousand)		(₹ in thousand)	
	For the year ended		For the year ended	
	31 March 2017		31 March 2016	
Legal and professional fees	200,225	13,431	225	15
Impairment of Intangibles	1,350,000	90,950	-	-
Total other expenses	1,550,225	104,381	225	15

9. EXCEPTIONAL ITEMS

Particulars	USD		USD	
	(₹ in thousand)		(₹ in thousand)	
	For the year ended		For the year ended	
	31 March 2017		31 March 2016	
Total exceptional items				